Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II trial assessing RE 104in Generalized Anxiety Disorder (GAD).

Trial Profile

Phase II trial assessing RE 104in Generalized Anxiety Disorder (GAD).

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 07 Nov 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Luvesilocin (Primary)
  • Indications Anxiety disorders
  • Focus Therapeutic Use
  • Acronyms RECLAIM

Most Recent Events

  • 07 Nov 2025 New trial record
  • 30 Sep 2025 According to Reunion Neuroscience media release, company expects to initiate this RECLAIM phase 2 trial in Generalized Anxiety Disorder (GAD) in 1Q 2026
  • 16 Sep 2025 According to the Reunion Neuroscience Media Release, the company announced the closing of its Series A financing. the Series A financing will be used to fully fund the REKINDLE Phase 2 trial in Adjustment Disorder (AjD) and to initiate the RECLAIM Phase 2 trial in Generalized Anxiety Disorder (GAD).

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top